08:15 uur 03-07-2019

BIOCORP voert exclusieve onderhandelingen met SANOFI om gebruik te maken van hun met MallyaTM verbonden apparaat met Sanofi’s geïntegreerde diabeteszorgplatform

  • BIOCORP ontvangt ​​vooruitbetaling van 4 miljoen euro

ISSOIRE, Frankrijk–(BUSINESS WIRE)–Regulatoir Nieuws:

BIOCORP (FR0012788065 – ALCOR/Eligible PEA PME) (Parijs: ALCOR), een Frans bedrijf dat is gespecialiseerd in de ontwikkeling en productie van medische apparaten en slimme systemen voor de levering van medicijnen, kondigt aan dat zij een exclusieve onderhandeling zijn aangegaan met SANOFI, een wereldwijde leider binnen de farmaceutische industrie, gericht op de introductie van hun met Mallya verbonden apparaat in het geïntegreerde diabeteszorgplatform van SANOFI.

Mallya is een slimme sensorkap die op een injectiepen wordt geklemd, waardoor het automatisch opnemen en verzenden van doseringsinformatie via een speciale mobiele applicatie mogelijk wordt. Mallya is het enige aangesloten apparaat voor injectiepennen dat is geëvalueerd om te voldoen aan de nauwkeurigheidseisen die nodig zijn voor een CE-klasse IIb-aanduiding voor medische apparaten van de Europese regelgevende instanties.

BIOCORP Enters Exclusive Negotiations With SANOFI to Use Their MallyaTM Connected Device With Sanofi’s Integrated Diabetes Care Platform

  • BIOCORP to receive upfront payment of 4 M€

ISSOIRE, France–(BUSINESS WIRE)– Regulatory News:

BIOCORP (FR0012788065 – ALCOR / Eligible PEA PME) (Paris:ALCOR), a French company specializing in the development and manufacturing of medical devices and smart drug delivery systems, announces that they have entered into an exclusive negotiation with SANOFI, a worldwide leader within the pharmaceutical industry, aimed at introducing their Mallya connected device into SANOFI’s integrated diabetes care platform.

Mallya is a smart sensor cap that clips onto an injection pen enabling automatic recording and transmission of dosage information via a dedicated mobile application. Mallya is the only connected device for injection pens which has been evaluated to meet the accuracy requirements needed for a CE Class IIb medical device designation by the European regulatory authorities.

Under the terms of these exclusive negotiations, BIOCORP will get an initial payment of €4 million from SANOFI to support related development activities.

Eric Dessertenne, Chief Operating Officer of BIOCORP, said: “This exciting first step towards a partnership with Sanofi, one of the three largest diabetes care companies, confirms our position as the world leader in connected devices. For us, this is a result of the promises we have made to our shareholders, employees and partners since our initial public offering in 2015. We are proud to bring a breakthrough device to the market to improve the daily lives of patients with diabetes. We believe our innovative Mallya has great potential to become the standard in its class and should contribute significantly, and in a short time, to our very strong growth.”

ABOUT BIOCORP

Founded in 2004 in Issoire (near Clermont-Ferrand), France, BIOCORP is a French company specializing in the development and manufacturing of medical devices and innovative drug delivery systems. It is listed as ‘Innovative Company’ by the French public investment bank Bpifrance. With over twenty years of experience and more than 30 manufactured products, BIOCORP is a key player in the industry, providing drug delivery solutions that meet the evolving needs of patients. Today, BIOCORP continues to innovate in medical plastics, its core business, and to market traditional devices (alternative to aluminum capsules, syringe and vial administration systems) that have been an important source of recurring income. Its solid expertise and capacity to innovate have allowed the company to develop new Internet-connected products, including MallyaTM, a smart cap for pen injectors that captures injection data and automatically transmits data to a mobile app, helping patients to manage their treatment. The company has a team of 45 employees. BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR).

For more information, please visit www.biocorpsys.com
Follow us on Twitter @BIOCORPSystems

Contacts

BIOCORP

Jacques Gardette

CEO

investisseurs@biocorp.fr

Éric Dessertenne

Chief Operating Officer

Sylvaine Dessard

Marketing & Communication Director

rp@biocorp.fr
+ 33 (0)6 88 69 72 85